MERIDIANChugai Pharmaceutical Co., Ltd.
Live view: Yahoo
Identity (GLEIF Global LEI Index)
| Field | Value | Class |
|---|---|---|
| Legal name | Chugai Pharmaceutical Co., Ltd. | SF |
| LEI | Unavailable | SF |
| Swiss UID | Not in GLEIF record | SF |
| Jurisdiction | Unavailable | SF |
| Legal address | Unavailable | SF |
| Headquarters | SF | |
| Entity status | Unavailable | SF |
| Geneva connection | unresolved | CM |
Listed securities (SIX Swiss Exchange issuer directory)
| ISIN | Ticker | MIC | Share class | Segment | Accounting standard | Next GM | Auditor | Prov. |
|---|---|---|---|---|---|---|---|---|
| 4519 | — | not announced | — | ⓘ |
Market snapshot
7325.00 JPY
Stale — 14 days old · delayed per exchange agreement · yahoo
| Metric | Value | Class |
|---|---|---|
| SMA 20 | 7414.70 | CM |
| SMA 50 | 7591.28 | CM |
| 52-week range position | 30% of range 6011.00–10455.00 | CM |
| Trend (SMA20 vs SMA50) | down | CM |
| History depth | 244 daily bars | SF |
Analyst price targets
| Low | Mean | Median | High | Analysts | Provider | As of |
|---|---|---|---|---|---|---|
| 8000.0 | 9853.333 | 9800.0 | 13500.0 | 15 | yfinance | 2026-07-19T11:08:10Z |
Consensus recommendation (provider-published): buy
Financials (latest reported period)
Most recent reported income-statement figures (company disclosure redistributed by the named source); absent figures stay absent — never estimated.
Period ending 2025-12-31 (annual) · reported in JPY
| Metric | Value | Class |
|---|---|---|
| Revenue | 1.3T JPY | SF |
| Gross profit | 894.3B JPY | SF |
| Operating income | 598.8B JPY | SF |
| EBITDA | 598.0B JPY | SF |
| Net income | 434.0B JPY | SF |
| EPS | 263.72 | SF |
2 further data fields this platform tracks — no connected source covers this issuer yet. Shown to demonstrate capacity; each populates automatically when a source does, and nothing is estimated in the meantime. Show what is tracked ›
Recent company events
News, insider transactions, congressional trading disclosures and analyst-estimate snapshots from connected sources, each with provenance. Analyst estimates are forecasts — never price targets.
No company events ingested yet — the FMP rotation families (news, insider transactions, congressional disclosures, analyst estimates) populate this once a key is configured. Nothing is invented in the meantime.
Segment & geographic revenue (company disclosures)
Figures parsed from filings and redistributed by the named provider; values are shown as reported and shares are Calculated Metrics with the formula in the column header.
No disclosed segment or geographic revenue ingested for this company yet. The Business Quant pipeline (SEC-parsed company disclosures) reaches US-listed issuers progressively within its daily budget; issuers that do not disclose segment detail keep this honest state.
How the company makes money
Business description and sector are sourced facts (Yahoo assetProfile / Wikidata / Wikipedia — source named per value); the registry-disclosed purpose follows. Disclosed segment/geographic revenue appears in the card above when the issuer reports it; official EDGAR-XBRL and ESEF facts feed the financials card since 2026-07-07. Nothing is estimated in the meantime.
Chugai Pharmaceutical Co., Ltd. is a drug manufacturer operating in Japan. It is a subsidiary controlled by Hoffmann-La Roche, which owns 62% of the company as of 30 June 2014. The company is headquartered in Tokyo. Osamu Nagayama is the current representative director and chairman. Tatsuro Kosaka is the current representative director, president and CEO. SF
source: wikipedia · retrieved 2026-07-19
Registry-disclosed purpose: Access currently requires credentials — the Swiss registry (Zefix) API returned HTTP 401 anonymously (verified 2026-07-02); registered-purpose text will populate once free Zefix credentials are configured in .env.
Regulators of highest concern
Ranked by maximum applicability of evidence-backed matches; when none exist yet, the jurisdictional supervision context derived from listing venue/domicile is shown instead — labelled, never asserted as a match.
Jurisdictional supervision context
No listing venue or domicile recorded by any connected source yet — no supervision context can be derived (and none is invented).
No evidence-backed matches yet — concern ranking derives only from evidence-backed matches; the authorities above are jurisdictional context from the recorded listing venue/domicile, not matches.
Regulatory exposure — matches with evidence
The price-impact column is a LABELLED INFERENCE (EBI): reasoning about whether and why the exposure could bear on the share price, derived from the regulation's type, region and topic and the match layer/direction. It is not an asserted fact and states no magnitude; the Applicability/Confidence/Exposure figures and the linked evidence remain the sourced basis.
No matches for this company under the current rule set.
Recent filings — potential impact inputs
A filing flags potential impact only via evidence-backed matching between its disclosed content and tracked measures.
No filings ingested for this company yet, and no listing venue/CIK is recorded from which the authoritative filing channel could be derived. ESEF/OAM filing content is a phased expansion tracked in the plan; filing-impact assessment activates only when real filings and matches coexist — it is never guessed.